In this section, you can find Press Releases concerning Neopharmed Gentili’s financial and corporate updates.

July 15, 2026


Neopharmed Gentili S.p.A. – Financial Results for Q2 2026

June 29, 2026


Notice of full redemption of Neopharmed Gentili S.P.A. of its Senior Secured Fixed Rate Notes due 2030 and its Senior Secured Floating Rate Notes due 2030

June 18, 2026


Neopharmed Gentili S.P.A. successfully completes the placement of its €890.0 million senior secured floating rate notes due 2033

June 15, 2026


Neopharmed Gentili S.p.A. Announces an offering of Senior Secured Floating Rate Notes due 2033

May 20, 2026


Neopharmed Gentili S.p.A. – Financial Results for Q1 2026

May 7, 2026


Neopharmed Gentili S.p.A. – Financial Results for Q1 2026

May 4, 2026


Neopharmed Gentili – through its Irish affiliate – acquires exclusive rights to Navenibart in Europe from BioCryst Pharmaceuticals

April 10, 2026


Neopharmed Gentili S.p.A. – Financial Results for FY 2025

December 18, 2025


Neopharmed Gentili announces Exclusive Licensing Agreement with Global Pharma Major Lupin

November 11, 2025


Neopharmed Gentili S.p.A. – Financial Results for Q3 2025

October 01, 2025


Neopharmed Gentili Completes Acquisition of European ORLADEYO® Business from BioCryst Pharmaceuticals

July 09, 2025


Neopharmed Gentili S.p.A. – Financial Results for Q2 2025

June 27, 2025


Neopharmed Gentili acquires the European ORLADEYO® Business from BioCryst Pharmaceuticals

May 09, 2025


Neopharmed Gentili S.p.A. – Financial Results for Q1 2025

April 07, 2025


Neopharmed Gentili S.p.A. – Financial Results for FY 2024

February 14, 2025


Neopharmed Gentili announces the private placement of €100.0 million Senior Secured Notes due 2030

February 04, 2025


Neopharmed Gentili acquires Metoclopramide product

November 07, 2024


Neopharmed Gentili S.p.A. – Financial Results for Q3 2024

July 18, 2024


Neopharmed Gentili S.p.A. announces CEO transition

July 8, 2024


Neopharmed Gentili S.p.A. – Financial Results for Q2 2024

June 4, 2024


Neopharmed Gentili S.p.A. – Financial Results for Q1 2024

May 16, 2024


Neopharmed Gentili S.p.A. – Creation of first ranking pledge over the share capital of Neopharmed Gentili S.p.A. and Valeas S.p.A.

March 28, 2024


Neopharmed Gentili S.P.A. successfully completes the placement of its €750.0 million senior secured notes due 2030